Ixabepilone, a New Treatment Option for Metastatic Breast Cancer
Authors:
- Deborah L. ToppmeyerDTDeborah L. Toppmeyer
- Susan GoodinSGSusan Goodin
- 1 October 2010
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 33 (5) , 516-521
Abstract
Patients with metastatic breast cancer (MBC) who develop resistance to anthracyclines and taxanes have limited therapeutic options. There is an unmet need for agents that can overcome tumor resistance and are effective in treating drug-resistant disease. The novel epothilone B analog, ixabepilone, binds to β-tubulin and stabilizes microtubules, leading to growth inhibition and apoptosis. Ixabepilone is able to overcome common mechanisms of resistance that limit the efficacy of many chemotherapeutic agents such as anthracyclines, taxanes, and capecitabine. Single-agent ixabepilone has clinical activity and a manageable safety profile against several different solid tumors including MBC, nonsmall cell lung cancer (NSCLC), and prostate cancer. Several phase II and III trials have demonstrated that ixabepilone-as monotherapy and in combination with capecitabine-is active in patients with pretreated or resistant MBC. Ixabepilone is the first epothilone approved for use as monotherapy or in combination with capecitabine in the treatment of metastatic or locally advanced breast cancer that is resistant or refractory to anthracyclines, taxanes, and/or capecitabine. Further clinical studies are evaluating the combination of ixabepilone with targeted agents such as trastuzumab or bevacizumab to further define the role of this novel agent in the treatment of MBC.Keywords
This publication has 41 references indexed in Scilit:
- Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast CancerJournal of Clinical Oncology, 2009
- Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline ChemotherapyJournal of Clinical Oncology, 2007
- Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulinsInternational Journal of Cancer, 2007
- Targeting the Microtubules in Breast Cancer Beyond Taxanes: The EpothilonesThe Oncologist, 2007
- A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group studyInvestigational New Drugs, 2006
- A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysCancer, 2005
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- Optimizing the treatment of metastatic breast cancerBreast Cancer Research and Treatment, 2005
- Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five DaysJournal of Clinical Oncology, 2003
- Monotherapy options in the management of metastatic breast cancerSeminars in Oncology, 2003